ClinicalTrials.gg
CompletedNCT00809965Updated Sep 17, 2014Results posted

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

A Phase 3 interventional study of Rivaroxaban 2.5 mg and Rivaroxaban 5 mg in Acute Coronary Syndrome, Myocardial Infarction and Myocardial Ischemia, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 584 sites in 43 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15,526
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing rivaroxaban in Acute Coronary Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Rivaroxaban · Acute Coronary Syndrome.

Enrollment
Largest of 13
15,526 · median 261
Started
2008
the only one that year
Phase 3
2 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 13 studies testing rivaroxaban in Acute Coronary Syndrome, this one has the largest enrollment, is the only one that started in 2008, is one of 2 in phase 3, and was the 2nd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

2 of the 13 studies testing rivaroxaban in Acute Coronary Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing rivaroxaban in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary syndrome compared with placebo.

Read the detailed description

Acute coronary syndrome (ACS) is a serious and life threatening condition. Following an acute coronary syndrome event patients are at risk of important additional clinical events such as death, myocardial infarction, and stroke. Six months after patients present with an index event of ST-segment myocardial infarction, approximately 15% will either have died or had another episode of myocardial ischemia, and a similar situation exists for non-ST-segment elevation myocardial infarction/unstable angina patients. This randomized; double-blind; placebo controlled study will evaluate the efficacy and safety of rivaroxaban in addition to standard care in patients with a recent ACS. Patients will be given rivaroxaban (2.5 mg twice daily or 5 mg twice daily) or placebo (twice daily) in addition to standard care.

03

Conditions studied

  • Acute Coronary Syndrome
  • Myocardial Infarction
  • Myocardial Ischemia
  • Unstable Angina

Keywords

  • Rivaroxaban
  • Acute Coronary Syndrome
  • ACS
  • Aspirin
  • Thienopyridine
  • Unstable Angina
  • Myocardial Infarction
  • Anticoagulation
  • Clopidogrel (Plavix)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be currently receiving aspirin therapy alone or in combination with a thienopyridine per national or local dosing recommendation
  • Have been hospitalized for symptoms suggestive of acute coronary syndrome that lasted at least 10 minutes at rest and occurred 48 hours or less before going to the hospital

Exclusion criteria

Exclusion Criteria:

  • Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding
  • Need for continued anticoagulant therapy
  • Significant renal impairment or known significant liver disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15,526 participants (actual)

Study arms

  • Experimental
    Rivaroxaban 2.5 mg bid

    One 2.5 mg rivaroxaban tablet twice daily for up to 6 months

    Drug: Rivaroxaban 2.5 mg · Drug: Standard of care

  • Experimental
    Rivaroxaban 5 mg bid

    One 5 mg rivaroxaban tablet twice daily for up to 6 months

    Drug: Rivaroxaban 5 mg · Drug: Standard of care

  • Placebo comparator
    Placebo

    One placebo tablet twice daily for up to 6 months

    Drug: Placebo · Drug: Standard of care

Interventions

06

What researchers measure

Primary outcomes

  1. The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke

    The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

    Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

Secondary outcomes

  1. The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke

    The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

    Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

  2. The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery

    The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

    Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

  3. The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization

    The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

    Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

  4. The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization

    The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

    Time frame: From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)

07

Results

Posted Jun 2, 2014

Participant flow

This study, an efficacy and safety study of rivaroxaban in patients with acute coronary syndrome, was conducted between 26 November 2008 and 19 September 2011. Patients were recruited from 766 study centers located in 44 countries worldwide.

Participant flow — Overall Study
MilestonePlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
Started517651745176
Treated/safety population512551155110
Modified intent-to-treat population511351145115
Completed439343994332
Not completed783775844
Withdrew: Death194147196
Withdrew: Lost to follow-up171018
Withdrew: Withdrawal by subject405448441
Withdrew: Other reason167170189

Outcome measures

PrimaryThe Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke

The percentage of patients with the first occurrence of the composite of death, myocardial infarction, or stroke. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

Time frame:
From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Reported as:
Number · Percentage of patients
The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke
Percentage of patientsPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke7.46.16.1
Statistical analysis
  • Placebo vs Rivaroxaban 2.5 mg Bid · Log Rank · p = 0.020 · Hazard ratio (hr): 0.84 · 95% CI 0.72 to 0.97Based upon the Cox proportional hazards model
  • Placebo vs Rivaroxaban 5 mg Bid · Log Rank · p = 0.028 · Hazard ratio (hr): 0.85 · 95% CI 0.73 to 0.98Based upon the Cox proportional hazards model
SecondaryThe Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke

The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

Time frame:
From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Reported as:
Number · Percentage of patients
The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke
Percentage of patientsPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
The Percentage of Patients With the Composite of All Cause Death, Myocardial Infarction, or Stroke7.56.36.3
Statistical analysis
  • Placebo vs Rivaroxaban 2.5 mg Bid · Log Rank · p = 0.016 · Hazard ratio (hr): 0.83 · 95% CI 0.72 to 0.97Based on the Cox proportional hazards model
  • Placebo vs Rivaroxaban 5 mg Bid · Log Rank · p = 0.025 · Hazard ratio (hr): 0.84 · 95% CI 0.73 to 0.98Based on the Cox proportional hazards model
SecondaryThe Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery

The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

Time frame:
From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Reported as:
Number · Percentage of patients
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery
Percentage of patientsPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Ischemic Stroke, or TIMI Major Bleeding Event Not Associated With Coronary Artery Bypass Graft Surgery7.67.17.2
Statistical analysis
  • Placebo vs Rivaroxaban 2.5 mg Bid · Log Rank · p = 0.320 · Hazard ratio (hr): 0.93 · 95% CI 0.81 to 1.07Based upon the Cox proportional hazards model
  • Placebo vs Rivaroxaban 5 mg Bid · Log Rank · p = 0.508 · Hazard ratio (hr): 0.95 · 95% CI 0.83 to 1.10Based upon the Cox proportional hazards model
SecondaryThe Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization

The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

Time frame:
From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Reported as:
Number · Percentage of patients
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization
Percentage of patientsPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Requiring Revascularization9.48.58.2
Statistical analysis
  • Placebo vs Rivaroxaban 2.5 mg Bid · Log Rank · p = 0.185 · Hazard ratio (hr): 0.92 · 95% CI 0.80 to 1.04Based upon the Cox proportional hazards model
  • Placebo vs Rivaroxaban 5 mg Bid · Log Rank · p = 0.081 · Hazard ratio (hr): 0.89 · 95% CI 0.78 to 1.01Based upon the Cox proportional hazards model
SecondaryThe Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization

The percentage of patients with the first occurrence of the composite endpoint. The statistical analysis was based on the time from randomization to the first occurrence of the event while on treatment.

Time frame:
From the time of randomization (Day 1) up to completion of the treatment phase (Month 6)
Reported as:
Number · Percentage of patients
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization
Percentage of patientsPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
The Percentage of Patients With the Composite of Cardiovascular Death, Myocardial Infarction, Stroke, or Severe Recurrent Ischemia Leading to Hospitalization8.77.37.6
Statistical analysis
  • Placebo vs Rivaroxaban 2.5 mg Bid · Log Rank · p = 0.011 · Hazard ratio (hr): 0.84 · 95% CI 0.73 to 0.96Based upon the Cox proportional hazards model
  • Placebo vs Rivaroxaban 5 mg Bid · Log Rank · p = 0.070 · Hazard ratio (hr): 0.88 · 95% CI 0.78 to 1.01Based upon the Cox proportional hazards model

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1,018/5,125 (19.9%)140/5,125 (2.7%)
Rivaroxaban 2.5 mg Bid—1,033/5,115 (20.2%)259/5,115 (5.1%)
Rivaroxaban 5 mg Bid—1,083/5,110 (21.2%)341/5,110 (6.7%)
Most frequent serious events
Showing 10 of 785
Most frequent serious events
EventPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
Angina UnstableCardiac disorders100/5125105/5115123/5110
Angina PectorisCardiac disorders118/512593/5115106/5110
Cardiac FailureCardiac disorders41/512556/511527/5110
Non-Cardiac Chest PainGeneral disorders39/512536/511548/5110
Chest PainGeneral disorders33/512547/511533/5110
PneumoniaInfections and infestations33/512537/511533/5110
Sudden DeathGeneral disorders36/512523/511529/5110
Gastrointestinal HaemorrhageGastrointestinal disorders11/512518/511532/5110
Atrial FibrillationCardiac disorders27/512527/511521/5110
Coronary Artery DiseaseCardiac disorders16/512526/511513/5110
Most frequent other events
Most frequent other events
EventPlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg Bid
EpistaxisRespiratory, thoracic and mediastinal disorders140/5125259/5115341/5110

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg BidTotal
<=18 years0000
Between 18 and 65 years3320323932109769
>=65 years1805187619005581
Age, Continuous
Age, Continuous(years)PlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg BidTotal
Mean61.5 ± 9.3861.8 ± 9.2261.9 ± 9.0061.7 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg BidTotal
Female1280128313163879
Male38453832379411471
Region of Enrollment
Region of Enrollment(participants)PlaceboRivaroxaban 2.5 mg BidRivaroxaban 5 mg BidTotal
Argentina118126158402
Australia172182150504
Belgium595753169
Brazil184171168523
Bulgaria258264268790
Canada675863188
Chile676578210
China281299302882
Colombia978487268
Croatia21192262
Czech Republic154158170482
Denmark35214197
Egypt634746156
France686772207
Germany10196122319
Greece19212767
Hungary147142122411
India4795074731459
Israel114122101337
Italy787777232
Japan131135131397
Latvia273340100
Lithuania595166176
Malaysia36332695
Mexico719686253
Morocco12222256
Netherlands131113124368
New Zealand28313897
Philippines1911838
Poland3323613561049
Portugal363643115
Romania10394107304
Russian Federation5865965691751
Serbia434529117
Slovakia675853178
South Korea574049146
Spain717376220
Sweden584144143
Thailand525038140
Tunisia606252174
Turkey373941117
Ukraine205210213628
United Kingdom799175245
United States243211224678
08

Study locations

584 sites
  • Birmingham, Alabama, United States
  • Geneva, Alabama, United States
  • Mobile, Alabama, United States
  • Anaheim, California, United States
  • Burbank, California, United States
  • Los Angeles, California, United States
  • Mission Hills, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Littleton, Colorado, United States
  • Jacksonville, Florida, United States
  • Jupiter, Florida, United States
  • Kissimmee, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Orlando, Florida, United States
  • Ormond Beach, Florida, United States
  • St Petersburg, Florida, United States
  • St. Petersburg, Florida, United States
  • Columbus, Georgia, United States
  • Rome, Georgia, United States
  • Aurora, Illinois, United States
  • Indianapolis, Indiana, United States
  • Merrillville, Indiana, United States
  • Munster, Indiana, United States
  • Valparaiso, Indiana, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • Lacombe, Louisiana, United States
  • Bethesda, Maryland, United States
  • Boston, Massachusetts, United States
  • Flint, Michigan, United States
  • Grand Blanc, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Kalamazoo, Michigan, United States
  • Mount Clemens, Michigan, United States
  • Petoskey, Michigan, United States
  • Tupelo, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Kalispell, Montana, United States
  • Bridgewater, New Jersey, United States
  • Linden, New Jersey, United States
  • Buffalo, New York, United States
  • Cortlandt Manor, New York, United States
  • Saratoga Springs, New York, United States
  • Stony Brook, New York, United States
  • Syracuse, New York, United States
  • Winston Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Dayton, Ohio, United States
  • Fairview Park, Ohio, United States
  • Bartlesville, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Doylestown, Pennsylvania, United States
  • Langhorne, Pennsylvania, United States
  • Ridley Park, Pennsylvania, United States
  • Sayre, Pennsylvania, United States
  • West Chester, Pennsylvania, United States
  • York, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Johnson City, Tennessee, United States
  • Memphis, Tennessee, United States
  • Amarillo, Texas, United States
  • Lubbock, Texas, United States
  • Odessa, Texas, United States
  • Tomball, Texas, United States
  • Salt Lake City, Utah, United States
  • Burlington, Vermont, United States
  • Danville, Virginia, United States
  • Roanoke, Virginia, United States
  • Spokane, Washington, United States
  • Wausau, Wisconsin, United States
  • Buenos Aires, Argentina
  • Cordoba, Argentina
  • Corrientes, Argentina
  • Junin, Argentina
  • La Plata, Argentina
  • Mar Del Plata, Argentina
  • Moron, Argentina
  • Morón, Argentina
  • Resistencia, Argentina
  • Rosario, Argentina
  • Salta, Argentina
  • San Luis, Argentina
  • Santa Fe, Argentina
  • Tucuman, Argentina
  • Bedford Park, Australia
  • Chermside N/A, Australia
  • Coffs Harbour South, Australia
  • Douglas, Australia
  • Epping, Australia
  • Fremantle, Australia
  • Heidelberg, Australia
  • Herston, Australia
  • Launceston, Australia
  • Milton, Australia
  • Newcastle, Australia
  • Parkville, Australia

Showing the first 100 of 584 sites across 43 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gibson WJ, Nafee T, Travis R, Yee M, Kerneis M, Ohman M, Gibson CM. Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. J Thromb Thrombolysis. 2020 Jan;49(1):1-9. doi: 10.1007/s11239-019-01940-8. PubMed 31535314 ↗
  • Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome. J Am Coll Cardiol. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055. PubMed 29976285 ↗
  • Cavender MA, Gibson CM, Braunwald E, Wiviott SD, Murphy SA, Toda Kato E, Plotnikov AN, Amuchastegui M, Oude Ophuis T, van Hessen M, Mega JL. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2015 Oct;4(5):468-74. doi: 10.1177/2048872614554109. Epub 2014 Oct 15. PubMed 25318481 ↗
  • Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW, Bhatt DL, Goto S, Cohen M, Mohanavelu S, Burton P, Stone G, Braunwald E; ATLAS-ACS 2 TIMI 51 Investigators. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol. 2013 Jul 23;62(4):286-90. doi: 10.1016/j.jacc.2013.03.041. Epub 2013 Apr 16. PubMed 23602776 ↗
  • Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013 May 7;61(18):1853-9. doi: 10.1016/j.jacc.2013.01.066. Epub 2013 Mar 7. PubMed 23500262 ↗
  • Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. PubMed 22077192 ↗
  • Gibson CM, Mega JL, Burton P, Goto S, Verheugt F, Bode C, Plotnikov A, Sun X, Cook-Bruns N, Braunwald E. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011 May;161(5):815-821.e6. doi: 10.1016/j.ahj.2011.01.026. PubMed 21570509 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 9 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2008
First posted
Dec 17, 2008
Start
Nov 2008
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Oct 11, 2012
Results first posted
Jun 2, 2014
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00809965
Collaborators
Bayer
Responsible party
Sponsor
First posted
Dec 17, 2008
Start date
Nov 2008
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Jun 2, 2014
Last update
Sep 17, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion